Fate Therapeutics Overview
Fate Therapeutics Target Price
Analysts' 12-month price predictions for FATE.
Share Price
$1.36
Average Target Price
$3.00
120.6% upside
120.6% upside1 analysts in the last 4 months
High: $3 | Low: $3
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-03-06 | Stifel Nicolaus | $3 | 120.6% upside |  |
| 2024-11-13 | BMO CapitalEtzer Darout | $5 | 267.6% upside | |
| 2024-08-14 | Stifel NicolausBenjamin Burnett | $5 | 267.6% upside | |
| 2024-06-17 | Piper SandlerEdward Tenthoff | $6 | 341.2% upside | |
| 2024-05-16 | H.C. WainwrightDebjit Chattopadhyay | $5 | 267.6% upside | |
| 2024-05-10 | Piper SandlerEdward Tenthoff | $4 | 194.1% upside | |
| 2024-05-10 | BMO CapitalEtzer Darout | $6 | 341.2% upside | |
| 2024-05-10 | Canaccord GenuityBill Maughan | $9 | 561.8% upside | |
| 2023-01-09 | Goldman Sachs | $4 | 194.1% upside | |
| 2023-01-06 | Morgan Stanley | $8 | 488.2% upside | |
| 2023-01-06 | Piper Sandler | $12 | 782.4% upside | |
| 2023-01-06 | BMO Capital | $7 | 414.7% upside | |
| 2023-01-05 | Truist FinancialRobyn Karnauskas | $7 | 414.7% upside | |
| 2022-12-15 | Goldman SachsAndrea Tan | $10 | 635.3% upside | |
| 2022-12-13 | Truist Financial | $46 | 3282.4% upside | |
| 2021-12-13 | OppenheimerMatthew Biegler | $135 | 9826.5% upside | |
| 2021-11-08 | CitigroupYigal Nochomovitz | $87 | 6297.1% upside | |
| 2021-11-05 | Roth CapitalAnthony Butler | $60 | 4311.8% upside | |
| 2021-10-25 | JefferiesMichael Yee | $145 | 10561.8% upside | |
| 2021-08-20 | Piper SandlerEdward Tenthoff | $113 | 8208.8% upside | |